These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness. Lechanteur A; Furst T; Evrard B; Delvenne P; Hubert P; Piel G Eur J Pharm Sci; 2016 Oct; 93():493-503. PubMed ID: 27593989 [TBL] [Abstract][Full Text] [Related]
3. Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions. Lechanteur A; Furst T; Evrard B; Delvenne P; Hubert P; Piel G Int J Pharm; 2015 Apr; 483(1-2):268-77. PubMed ID: 25701628 [TBL] [Abstract][Full Text] [Related]
4. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes. Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847 [TBL] [Abstract][Full Text] [Related]
5. PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. Belletti D; Tosi G; Forni F; Lagreca I; Barozzi P; Pederzoli F; Vandelli MA; Riva G; Luppi M; Ruozi B Eur J Pharm Biopharm; 2016 Feb; 99():7-17. PubMed ID: 26625717 [TBL] [Abstract][Full Text] [Related]
6. Effect of PEG anchor in PEGylation of folate-modified cationic liposomes with PEG-derivatives on systemic siRNA delivery into the Tumor. Tang M; Sakasai S; Onishi H; Kawano K; Hattori Y J Drug Target; 2023 Jan; 31(1):74-88. PubMed ID: 35864749 [TBL] [Abstract][Full Text] [Related]
7. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes. Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333 [TBL] [Abstract][Full Text] [Related]
8. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma. Liu WL; Green N; Seymour LW; Stevenson M Cancer Gene Ther; 2009 Oct; 16(10):764-75. PubMed ID: 19363466 [TBL] [Abstract][Full Text] [Related]
9. The HPV16 E6, E7/miR-23b-3p/ICAT signaling axis promotes proliferation, migration, invasion and EMT of cervical cancer cells. Hu J; Liao D; Sun Z; Ren W; Zhao L; Fang Y; Hu K; Yu H; Liu S; Zhou L; He T; Zhang Y Carcinogenesis; 2023 May; 44(3):221-231. PubMed ID: 36847693 [TBL] [Abstract][Full Text] [Related]
10. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35). McFarlane M; MacDonald AI; Stevenson A; Graham SV J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103 [TBL] [Abstract][Full Text] [Related]
11. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502 [TBL] [Abstract][Full Text] [Related]
12. Human Papillomavirus Type 16 Circular RNA Is Barely Detectable for the Claimed Biological Activity. Yu L; Zheng ZM mBio; 2022 Feb; 13(1):e0359421. PubMed ID: 35038914 [TBL] [Abstract][Full Text] [Related]
13. Fused toes homolog, a potential molecular regulator of human papillomavirus type 16 E6 and E7 oncoproteins in cervical cancer. D S P; Chaturvedi PK; Krishnamoorthy D; Seo YS; Thippana M; Park WY PLoS One; 2022; 17(4):e0266532. PubMed ID: 35421154 [TBL] [Abstract][Full Text] [Related]
14. E6/E7 oncoproteins of high risk HPV-16 upregulate MT1-MMP, MMP-2 and MMP-9 and promote the migration of cervical cancer cells. Zhu D; Ye M; Zhang W Int J Clin Exp Pathol; 2015; 8(5):4981-9. PubMed ID: 26191191 [TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes. Nishida H; Matsumoto Y; Kawana K; Christie RJ; Naito M; Kim BS; Toh K; Min HS; Yi Y; Matsumoto Y; Kim HJ; Miyata K; Taguchi A; Tomio K; Yamashita A; Inoue T; Nakamura H; Fujimoto A; Sato M; Yoshida M; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Nishiyama N; Kataoka K; Osuga Y; Fujii T J Control Release; 2016 Jun; 231():29-37. PubMed ID: 26979870 [TBL] [Abstract][Full Text] [Related]
16. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines. Adhim Z; Otsuki N; Kitamoto J; Morishita N; Kawabata M; Shirakawa T; Nibu K Acta Otolaryngol; 2013 Jul; 133(7):761-71. PubMed ID: 23638950 [TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effect of RNA interference on expression of HPV16 E6 oncogene in cervical cancer cell line CaSki]. Niu XY; Peng ZL; Wang H Ai Zheng; 2004 Nov; 23(11):1257-62. PubMed ID: 15522169 [TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by chitosan/HPV16 E7 siRNA complexes in cervical cancer cells. Yang J; Li S; Guo F; Zhang W; Wang Y; Pan Y Mol Med Rep; 2013 Mar; 7(3):998-1002. PubMed ID: 23258711 [TBL] [Abstract][Full Text] [Related]
19. Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Zhou J; Peng C; Li B; Wang F; Zhou C; Hong D; Ye F; Cheng X; Lü W; Xie X Gynecol Oncol; 2012 Feb; 124(2):296-302. PubMed ID: 22056554 [TBL] [Abstract][Full Text] [Related]
20. The combinational effect of E6/E7 siRNA and anti-miR-182 on apoptosis induction in HPV16-positive cervical cells. Javadi H; Lotfi AS; Hosseinkhani S; Mehrani H; Amani J; Soheili ZS; Hojati Z; Kamali M Artif Cells Nanomed Biotechnol; 2018; 46(sup2):727-736. PubMed ID: 29873516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]